Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
Ioanna Andreadou, Panagiotis Efentakis, Evangelos Balafas, Gabriele Togliatto, Constantinos H Davos, Aimilia Varela, Constantinos A Dimitriou, Panagiota-Efstathia Nikolaou, Eirini Maratou, Vaia Lambadiari, Ignatios Ikonomidis, Nikolaos Kostomitsopoulos, Maria F Brizzi, George Dimitriadis, Efstathios K Iliodromitis, Ioanna Andreadou, Panagiotis Efentakis, Evangelos Balafas, Gabriele Togliatto, Constantinos H Davos, Aimilia Varela, Constantinos A Dimitriou, Panagiota-Efstathia Nikolaou, Eirini Maratou, Vaia Lambadiari, Ignatios Ikonomidis, Nikolaos Kostomitsopoulos, Maria F Brizzi, George Dimitriadis, Efstathios K Iliodromitis
Abstract
Empagliflozin (EMPA), a drug approved for type 2 diabetes management, reduced cardiovascular death but is unknown if it reduces myocardial infarction. We sought to investigate: (i) the effect of EMPA on myocardial function and infarct size after ischemia/reperfusion in mice fed with western diet (WD), (ii) the underlying signaling pathways, (iii) its effects on cell survival in rat embryonic-heart-derived cardiomyoblasts (H9C2) and endothelial cells (ECs). To facilitate the aforementioned aims, mice were initially randomized in Control and EMPA groups and were subjected to 30 min ischemia and 2 h reperfusion. EMPA reduced body weight, blood glucose levels, and mean arterial pressure. Cholesterol, triglyceride, and AGEs remained unchanged. Left ventricular fractional shortening was improved (43.97 ± 0.92 vs. 40.75 ± 0.61%) and infarct size reduced (33.2 ± 0.01 vs. 17.6 ± 0.02%). In a second series of experiments, mice were subjected to the above interventions up to the 10th min of reperfusion and myocardial biopsies were obtained for assessment of the signaling cascade. STAT3 was increased in parallel with reduced levels of malondialdehyde (MDA) and reduced expression of myocardial iNOS and interleukin-6. Cell viability and ATP content were increased in H9C2 and in ECs. While, STAT3 phosphorylation is known to bestow infarct sparing properties through interaction with mitochondria, we observed that EMPA did not directly alter the mitochondrial calcium retention capacity (CRC); therefore, its effect in reducing myocardial infarction is STAT3 dependent. In conclusion, EMPA improves myocardial function and reduces infarct size as well as improves redox regulation by decreasing iNOS expression and subsequently lipid peroxidation as shown by its surrogate marker MDA. The mechanisms of action implicate the activation of STAT3 anti-oxidant and anti-inflammatory properties.
Keywords: STAT3 pathway; cardiac function; cardioprotection; empagliflozin; infarct size; molecular signaling.
Figures
References
- Andreadou I., Bibli S. I., Mastromanolis E., Zoga A., Efentakis P., Papaioannou N., et al. . (2015). Transient carotid ischemia as a remote conditioning stimulus for myocardial protection in anesthetized rabbits: insights into intracellular signaling. Int. J. Cardiol. 184, 140–151. 10.1016/j.ijcard.2015.01.079
- Andreadou I., Farmakis D., Prokovas E., Sigala F., Zoga A., Spyridaki K., et al. (2012). Short-term statin administration in hypercholesterolemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase and nitro-oxidative stress. Cardiovasc. Res. 94, 501–509. 10.1093/cvr/cvs121
- Andreadou I., Iliodromitis E. K., Mikros E., Bofilis E., Zoga A., Constantinou M., et al. (2004). Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress. Free Radic. Biol. Med. 37, 500–510. 10.1016/j.freeradbiomed.2004.05.005
- Baartscheer A., Schumacher C. A., Wust R. C., Fiolet J. W., Stienen G. J., Coronel R., et al. . (2017). Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60, 568–573. 10.1007/s00125-016-4134-x
- Baldanzi G., Filigheddu N., Cutrupi S., Catapano F., Bonissoni S., Fubini A., et al. . (2002). Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J. Cell Biol. 159, 1029–1037. 10.1083/jcb.200207165
- Bernardi P., Di Lisa F. (2015). The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J. Mol. Cell. Cardiol. 78, 100–106. 10.1016/j.yjmcc.2014.09.023
- Bibli S. I., Andreadou I., Chatzianastasiou A., Tzimas C., Sanoudou D., Kranias E., et al. . (2015). Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban pathway. Cardiovasc. Res. 106, 432–442. 10.1093/cvr/cvv129
- Bibli S. I., Andreadou I., Glynos C., Chatzianastasiou A., Toumpanakis D., Zakynthinos S. G., et al. . (2016). Exposure to cigarette smoke abrogates the beneficial effect of ischemic postconditioning. Am. J. Physiol. Heart Circ. Physiol. 311, H1321–H1332. 10.1152/ajpheart.00925.2015
- Calvert J. W., Gundewar S., Jha S., Greer J. J., Bestermann W. H., Tian R., et al. . (2008). Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 57, 696–705. 10.2337/db07-1098
- Chatzianastasiou A., Bibli S. I., Andreadou I., Efentakis P., Kaludercic N., Wood M. E., et al. . (2016). Cardioprotection by H2S donors: nitric oxide-dependent and independent mechanisms. J. Pharmacol. Exp. Ther. 358, 431–440. 10.1124/jpet.116.235119
- Chen J., Fan F., Wang J. Y., Long Y., Gao C. L., Stanton R. C., et al. . (2017). The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci. Rep. 7:44128. 10.1038/srep44128
- Cheng S. T., Chen L., Li S. Y., Mayoux E., Leung P. S. (2016). The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes. PLoS ONE 11:e0147391. 10.1371/journal.pone.0147391
- Fitchett D., Zinman B., Wanner C., Lachin J. M., Hantel S., Salsali A., et al. . (2016). Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur. Heart J. 37, 1526–1534. 10.1093/eurheartj/ehv728
- Gordon J. W., Shaw J. A., Kirshenbaum L. A. (2011). Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ. Res. 108, 1122–1132. 10.1161/CIRCRESAHA.110.226928
- Habibi J., Aroor A. R., Sowers J. R., Jia G., Hayden M. R., Garro M., et al. . (2017). Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc. Diabetol. 16:9. 10.1186/s12933-016-0489-z
- Hausenloy D. J., Barrabes J. A., Bøtker H. E., Davidson S. M., Di Lisa F., Downey J., et al. . (2016). Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res. Cardiol. 111:70. 10.1007/s00395-016-0588-8
- Hawley S. A., Ford R. J., Smith B. K., Gowans G. J., Mancini S. J., Pitt R. D., et al. . (2016). The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65, 2784–2794. 10.2337/db16-0058
- Heusch G. (2015). Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ. Res. 116, 674–699. 10.1161/CIRCRESAHA.116.305348
- Kleinbongard P., Skyschally A., Gent S., Pesch M., Heusch G. (2017). STAT3 as a common signal of ischemic conditioning: a lesson on “rigor and reproducibility” in preclinical studies on cardioprotection. Basic Res. Cardiol. 113, 3 10.1007/s00395-017-0660-z
- Lee T. M., Chang N. C., Lin S. Z. (2017). Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 104, 298–310. 10.1016/j.freeradbiomed.2017.01.035
- Miki T., Itoh T., Sunaga D., Miura T. (2012). Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc. Diabetol. 11:67. 10.1186/1475-2840-11-67
- Oelze M., Kroller-Schon S., Welschof P., Jansen T., Hausding M., Mikhed Y., et al. . (2014). The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE 9:e112394. 10.1371/journal.pone.0112394
- Pagliaro P., Penna C. (2015). Redox signalling and cardioprotection: translatability and mechanism. Br. J. Pharmacol. 172, 1974–1995. 10.1111/bph.12975
- Panchapakesan U., Pegg K., Gross S., Komala M. G., Mudaliar H., Forbes J., et al. . (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS ONE 8:e54442. 10.1371/journal.pone.0054442
- Papathanasiou S., Rickelt S., Soriano M. E., Schips T. G., Maier H. J., Davos C. H., et al. . (2015). Tumor necrosis factor-alpha confers cardioprotection through ectopic expression of keratins K8 and K18. Nat. Med. 21, 1076–1084. 10.1038/nm.3925
- Park H., Ku S. H., Park H., Hong J., Kim D., Choi B. R., et al. . (2015). RAGE siRNA-mediated gene silencing provides cardioprotection against ventricular arrhythmias in acute ischemia and reperfusion. J. Control. Release 217, 315–326. 10.1016/j.jconrel.2015.09.006
- Penna C., Perrelli M. G., Pagliaro P. (2013). Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid. Redox Signal. 18, 556–599. 10.1111/bph.12975
- Phillips J. W., Barringhaus K. G., Sanders J. M., Yang Z., Chen M., Hesselbacher S., et al. . (2003). Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 108, 1994–1999. 10.1161/01.CIR.0000092886.52404.50
- Sag C. M., Wagner S., Maier L. S. (2013). Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes. Free Radic. Biol. Med. 63, 338–349. 10.1016/j.freeradbiomed.2013.05.035
- Steven S., Oelze M., Hanf A., Kröller-Schön S., Kashani F., Roohani S., et al. . (2017). The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13, 370–385. 10.1016/j.redox.2017.06.009
- Su S. A., Yang D., Zhu W., Cai Z., Zhang N., Zhao L., et al. . (2016). Interleukin-17A mediates cardiomyocyte apoptosis through Stat3-iNOS pathway. Biochim. Biophys. Acta 1863, 2784–2794. 10.1016/j.bbamcr.2016.08.013
- Surwit R. S., Kuhn C. M., Cochrane C., McCubbin J. A., Feinglos M. N. (1988). Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37, 1163–1167. 10.2337/diab.37.9.1163
- Togliatto G., Trombetta A., Dentelli P., Rosso A., Brizzi M. F. (2011). MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage. Diabetologia 54, 1930–1940. 10.1007/s00125-011-2125-5
- Vettor R., Inzucchi S. E., Fioretto P. (2017). The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia 60, 395–398. 10.1007/s00125-016-4194-y
- Wenzel P., Hink U., Oelze M., Schuppan S., Schaeuble K., Schildknecht S., et al. . (2007). Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem. 282, 792–799. 10.1074/jbc.M606477200
- Yanagisawa K., Makita Z., Shiroshita K., Ueda T., Fusegawa T., Kuwajima S., et al. . (1998). Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metab. Clin. Exp. 47, 1348–1353. 10.1016/S0026-0495(98)90303-1
- Yu Z., Zhang W., Kone B. C. (2002). Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem. J. 367, 97–105. 10.1042/bj20020588
Source: PubMed